Kronos Bio, Inc.
KRONHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $9.8M | $6.3M | $0 | — | — | — |
| Operating income | −$92.9M | −$122.1M | −$137.1M | −$151.4M | −$58.0M | −$16.8M |
| Net income | −$86.1M | −$112.7M | −$133.2M | −$151.1M | −$88.4M | −$16.1M |
| Total assets | $124.4M | $213.3M | $294.9M | $391.5M | $512.0M | $102.7M |
| Total liabilities | $36.8M | $54.2M | $50.4M | $46.4M | $46.4M | $3.0M |
| Equity | $87.6M | $159.1M | $244.5M | $345.1M | $465.5M | −$23.2M |
| EPS (diluted) | $-1.43 | $-1.95 | $-2.37 | $-2.76 | — | — |
| Shares out. | 60.1M | 57.6M | 56.6M | 56.0M | 54.1M | 5.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- −943.2%
- Net margin
- −874.1%
- Return on equity
- −98.3%
- Return on assets
- −69.2%
- Return on capital (ROCE)
- −85.2%
- Liabilities / assets
- 29.6%
- Debt / equity
- 0.42×
- Book value / share
- $1.46
- Revenue growth (YoY)
- 56.6%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -12.84distress
- Accruals / assets
- −16.6%clean
- Piotroski F-Score
- 4/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 1 severe● 3 warning● 3 good- Altman Z″ in the distress zone
- Operating losses (negative operating margin)
- Reported a net loss
- Negative operating cash flow
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Bischofberger Norbert WActivist (13D)Jun 20, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| Jun 13, 2025 | 877,480 | 1.0 | +16.3% |
| May 30, 2025 | 754,265 | 1.0 | +37.7% |
| May 15, 2025 | 547,885 | 1.0 | -18.4% |
| Apr 30, 2025 | 671,404 | 8.0 | +0.3% |
| Apr 15, 2025 | 669,437 | 6.0 | +9.4% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsJun 20, 2025
- Terminated a material agreement · New financial obligationJun 5, 2025
- Entered a material agreement · Regulation FD disclosureMay 1, 2025
- Terminated a material agreementApr 10, 2025
- Results of operationsMar 18, 2025
- Terminated a material agreementDec 27, 2024
- Costs from exit or disposal · Director / officer changeNov 27, 2024
- Results of operationsNov 13, 2024
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.